S&P 500   3,323.22 (-0.14%)
DOW   27,199.51 (+-0.01%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,323.22 (-0.14%)
DOW   27,199.51 (+-0.01%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,323.22 (-0.14%)
DOW   27,199.51 (+-0.01%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,323.22 (-0.14%)
DOW   27,199.51 (+-0.01%)
QQQ   270.71 (-0.13%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
Log in

Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Sell at ValuEngine

Last updated on Monday, August 3, 2020 | 2020 MarketBeat

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities research analysts at ValuEngine from a "hold" rating to a "sell" rating in a research note issued on Monday, ValuEngine reports.

A number of other equities research analysts also recently weighed in on the stock. BidaskClub downgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. Jefferies Financial Group assumed coverage on shares of Supernus Pharmaceuticals in a report on Monday, June 15th. They issued a "hold" rating and a $24.00 price objective for the company. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $25.00 to $31.00 in a report on Tuesday, June 16th. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating and set a $26.00 price objective for the company in a report on Saturday. Finally, Stifel Nicolaus dropped their price objective on shares of Supernus Pharmaceuticals from $25.00 to $24.00 and set a "hold" rating for the company in a report on Thursday, April 16th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Supernus Pharmaceuticals currently has an average rating of "Hold" and an average price target of $31.00.

Shares of SUPN traded up $1.03 during mid-day trading on Monday, reaching $23.29. The company had a trading volume of 464,124 shares, compared to its average volume of 561,583. The company's 50 day simple moving average is $23.62 and its 200 day simple moving average is $21.81. Supernus Pharmaceuticals has a 1-year low of $13.12 and a 1-year high of $33.43. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.16 and a current ratio of 3.31. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of 10.73 and a beta of 1.55.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.10. Supernus Pharmaceuticals had a net margin of 28.90% and a return on equity of 20.31%. The company had revenue of $94.98 million for the quarter, compared to the consensus estimate of $84.01 million. During the same period last year, the company posted $0.34 EPS. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. As a group, equities analysts forecast that Supernus Pharmaceuticals will post 1.49 earnings per share for the current fiscal year.

In other news, CFO Gregory S. Patrick sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $25.03, for a total transaction of $375,450.00. Following the sale, the chief financial officer now directly owns 61,057 shares in the company, valued at approximately $1,528,256.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 30,920 shares of company stock worth $745,035 over the last quarter. Company insiders own 7.86% of the company's stock.

A number of institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC raised its stake in Supernus Pharmaceuticals by 45.1% in the 2nd quarter. ProShare Advisors LLC now owns 15,904 shares of the specialty pharmaceutical company's stock valued at $378,000 after acquiring an additional 4,942 shares during the period. Comerica Bank raised its stake in Supernus Pharmaceuticals by 8.2% in the 2nd quarter. Comerica Bank now owns 55,225 shares of the specialty pharmaceutical company's stock valued at $1,303,000 after acquiring an additional 4,179 shares during the period. Ingalls & Snyder LLC raised its stake in Supernus Pharmaceuticals by 0.7% in the 2nd quarter. Ingalls & Snyder LLC now owns 71,188 shares of the specialty pharmaceutical company's stock valued at $1,691,000 after acquiring an additional 500 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $240,000. Finally, Wakefield Asset Management LLLP bought a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $518,000. Institutional investors and hedge funds own 92.73% of the company's stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Read More: What is a resistance level?

To view ValuEngine's full report, visit ValuEngine's official website.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Virus-Resistant Retail Stocks to Own Now

The U.S. economy contracted by 5% in the first quarter. That was slightly larger than the 4.8 decline that was previously forecast. On the same day that GDP was released, we also learned that the ranks of those filing for unemployment claims exceeded 40 million.

But as sobering as those numbers are, they’re not completely surprising. The U.S. economy was effectively shut down as citizens did their part to slow the spread of the novel coronavirus. But the cost of those efforts is just being measured.

And one of those measurements comes in the all-important Consumer Confidence Index. The index ticked up slightly in May to 86.6. While this number is about 30% lower than where the index sat In February, it’s significantly higher than where it sat at the trough of the financial crisis and subsequent recession.

And a big reason for that is that while the brick-and-mortar economy shut down, the digital economy helped give the economy a pulse.

Consumption is a key part of our economy. That’s why consumer confidence makes up 70% of the U.S. economy. And one of the key ways that consumers express that confidence or lack thereof, is in the retail sector.

For the last few years, the story of retail has been about which retailers were going to be able to successfully compete in the e-commerce space that is still owned by Amazon (NASDAQ:AMZN). Sadly, we’re discovering that some companies, like J.C. Penney, were late to adapt in a meaningful way. But that isn’t the case for all retailers.

In this special presentation, we are identifying 7 retail stocks that have done well through this turbulent time and should use that as a springboard to continued growth.

View the "7 Virus-Resistant Retail Stocks to Own Now".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.